Life Sciences

  • April 21, 2026

    Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit

    A Novo Nordisk unit must face a former finance director's lawsuit claiming she was fired because she was an older woman who complained about a male co-worker's behavior, with a North Carolina federal judge ruling her allegations were detailed enough to stay in court.

  • April 21, 2026

    Purdue Pharma Sentencing Punted For In-Person Attendance

    A New Jersey federal judge delayed Oxycontin maker Purdue Pharma's criminal sentencing by a week, saying rescheduling would give an in-person attendance option to hundreds of observers who tuned in virtually Tuesday.

  • April 21, 2026

    Ga. Justices Confront Fed, State Power Divide In Bio-Lab Suit

    Georgia's highest court seemed to struggle Tuesday with whether it had the authority to tell a federal judge if residents suing chlorine products company Bio-Lab Inc. over the aftermath of a 2024 fire could ask for medical monitoring as part of their class action.

  • April 21, 2026

    Philly Zantac Judge Again Declines To Recuse From Cases

    A Philadelphia judge overseeing the Zantac mass tort litigation against GlaxoSmithKline has once again denied a motion to recuse himself from the cases, claiming that his wife's affiliation with a firm representing a defendant in the litigation did not present a conflict that required him to step away.

  • April 20, 2026

    Armistice Head Testifies He Accidentally Deleted Texts

    Armistice Capital's founder, who is facing investor claims that the hedge fund dumped its artificially inflated shares in pharmaceutical company Vaxart for $250 million, told a California federal jury Monday that during a physical therapy session held over Skype, he accidentally deleted key text messages with another Armistice executive.

  • April 20, 2026

    Beasley Allen Pro Hac Vice Revoked In Philly J&J Talc Cases

    A Pennsylvania state court has booted Beasley Allen Law Firm attorneys from representing consumers in nine cases that link Johnson & Johnson's talcum powder to ovarian cancer, saying their pro hac vice admission was inappropriate given the firm's dealings with an attorney who previously represented the company.

  • April 20, 2026

    Quinn Emanuel May Face More Sanctions In Guardant Fight

    Guardant Health Inc. urged a California federal judge on Monday to make Quinn Emanuel pay nearly $1.3 million on top of $3 million in sanctions already imposed over misrepresentations lawyers made representing its rival Natera Inc., prompting the judge to criticize Quinn Emanuel lawyers for making distinctions so fine they veer into misrepresentation.

  • April 20, 2026

    Philip Morris Unfairly Gains From Label Ruling, 11th Circ. Told

    Philip Morris cannot be the only company allowed to not follow a rule requiring cigarette makers to add graphic warnings to their labels, R.J. Reynolds and a coalition of tobacco businesses have told the Eleventh Circuit, suggesting that consumers might assume its cigarettes are safer than theirs.

  • April 20, 2026

    ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says

    Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the U.S. Food and Drug Administration, according to a shareholder derivative suit in California federal court.

  • April 20, 2026

    SEC Says Adviser Traded On Firm Clients' Confidential Info

    The U.S. Securities and Exchange Commission sued an ex-investment advisory firm associate in Manhattan federal court on Monday, accusing him of using a close relative's brokerage account to trade ahead of market-moving announcements by three biopharmaceutical and biotechnology companies that his firm was researching.

  • April 20, 2026

    PFAS Plaintiffs Say Midcase Appeal Would 'Derail' Litigation

    Georgia residents accusing carpet and chemicals manufacturers of contaminating their properties with forever chemicals urged a state court to reject Shaw Industries' bid to appeal the recent nondismissal of their claims, arguing the request is the carpet company's latest "attempt to derail this litigation."

  • April 20, 2026

    PBMs Fail To Freeze Discovery In Mich.'s Drug-Pricing Case

    A pending motion to dismiss the Michigan attorney general's drug-pricing case against multiple pharmacy benefit managers does not preclude the PBMs from handing over agreements between PBMs and pharmacies to the state, a federal judge said in a motion hearing Monday.

  • April 20, 2026

    She Has A Point: Fish & Richardson's Nitika Gupta Fiorella

    Fish & Richardson PC principal Nitika Gupta Fiorella is "a no-stone-unturned, always super prepared" lawyer who "epitomizes professionalism and respect," according to Finnegan Henderson Farabow Garrett & Dunner LLP partner Cora Holt.

  • April 20, 2026

    Doctors Fueled Man's Fatal Opioid Addiction, Philly Jury Told

    Counsel for the family of a man who died of an opioid overdose at age 26 told a Philadelphia jury that his doctors were responsible for pushing treatment plans that allowed him to develop an opioid addiction, leading to his untimely death, pointing to both physicians being paid speakers for the pharmaceutical companies whose medications they prescribed.

  • April 20, 2026

    Justices Mull Limits On Federal Review Of State Cases

    The U.S. Supreme Court on Monday wrestled with the potential impact of reining in — or even scrapping altogether — a 100-year-old doctrine that curbs litigants' ability to go to federal court to try to overturn a state court loss.

  • April 20, 2026

    House Panel Probes Reports Of Missing, Killed Scientists

    Two Republican U.S. congressmen announced a probe Monday into reports of about a dozen scientists or government employees with ties to American nuclear and space programs who were killed or reported missing, penning letters seeking information from NASA, the Department of Energy, the FBI and the Defense Department.

  • April 20, 2026

    GSK, Moderna Both Ordered To Provide More Info In Vax Fight

    A special master overseeing discovery disputes in GlaxoSmithKline's infringement suits over Moderna's COVID-19 and related respiratory syncytial virus vaccines ordered both companies to furnish information to each other, including financial data and licenses, according to an opinion unsealed Monday.

  • April 20, 2026

    Trump Orders Agencies To Fast-Track Psychedelic Therapies

    President Donald Trump on Saturday announced that his administration would instruct federal agencies to accelerate investigations into new therapies derived from psychedelic drugs and streamline patients' access to the treatments.

  • April 20, 2026

    White & Case Partner Moves To A&O Shearman In DC

    Allen Overy Shearman Sterling has hired a career White & Case LLP partner in Washington, D.C., who had spent the past 13 years there working with antitrust and other matters, the firm announced Monday.

  • April 20, 2026

    Kirkland, Goodwin Guide Lilly's Potential $7B Kelonia Buy

    Kirkland & Ellis LLP-advised pharmaceutical giant Eli Lilly & Co. on Monday announced plans to acquire clinical-stage biotechnology company Kelonia Therapeutics, led by Goodwin Procter LLP, in a deal worth up to $7 billion.

  • April 20, 2026

    High Court Won't Hear 3rd Circ. J&J Class Cert. Appeal

    The U.S. Supreme Court on Monday said it won't review a class certification challenge in a securities class action over Johnson & Johnson's cancer-related talc products in the latest development in a closely watched dispute over how courts evaluate class certification in shareholder suits.

  • April 20, 2026

    Justices Won't Consider IP Theft Allegations Against Akin

    The U.S. Supreme Court on Monday rejected a former Cornell University graduate student's petition trying to revive his malpractice suit against Akin Gump Strauss Hauer & Feld LLP stemming from patent litigation against Illumina Inc. over DNA sequencing intellectual property.

  • April 17, 2026

    Bayer Loses Bid To Block J&J's Cancer Drug Survival Claims

    A Manhattan federal judge Friday refused to block Johnson & Johnson from advertising its prostate cancer drug as having a lower risk of death compared with Bayer's medication, saying Bayer has not shown it is likely to succeed on its claims that its rival's advertising campaign is false or misleading.

  • April 17, 2026

    ITC Clears Apple's Redesigned Apple Watch For Import

    The U.S. International Trade Commission on Friday signed off on an administrative law judge's finding that Apple has sufficiently redesigned its smartwatch so it doesn't infringe Masimo Corp.'s patents and is therefore not bound by a 2023 import ban.

  • April 17, 2026

    Missed Deadline Fatal To Patient's Stapler Suit, 4th Circ. Says

    The Fourth Circuit ruled Friday that a surgery patient's missed expert disclosure deadline rightfully ended his case seeking to hold Johnson & Johnson subsidiary Ethicon Endo-Surgery LLC liable for allegedly faulty staples used in his procedure.

Expert Analysis

  • How 11th Circ.'s Zafirov Decision Could Upend Qui Tam Cases

    Author Photo

    Oral argument before the Eleventh Circuit last month in U.S. ex rel. Zafirov v. Florida Medical Associates suggests that the court may affirm a lower court's opinion that the qui tam provisions of the False Claims Act are unconstitutional — which could wreak havoc on pending and future qui tam cases, say attorneys at Morgan Lewis.

  • Key Trends For Life Sciences Cos. To Watch In 2026

    Author Photo

    Following a year of drastic change at the U.S. Food and Drug Administration, two themes are likely to drive the coming year — a commitment to lowering the cost of drugs and an inherent tension between the priorities of the health agencies and the broader administration, say attorneys at Sheppard Mullin.

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • Trending At The PTAB: The Policies That Are Redefining IPR

    Author Photo

    The evolution of the Patent Trial and Appeal Board's inter partes review institution regime last year, coupled with the policy considerations behind that evolution, marks a shift toward greater gatekeeping of the U.S. Patent and Trademark Office's resources and patent enforcement rights, say attorneys at Finnegan.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Trending At The PTAB: The Journey Of IPR Institution In 2025

    Author Photo

    Over the course of 2025, inter partes review institution at the Patent Trial and Appeal Board evolved into a more restrictive, policy-driven regime with reshaped discretionary briefing and assessment, and increasing procedural requirements, say attorneys at Finnegan.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.